restrictive use policy

Post on 15-Jan-2016

42 Views

Category:

Documents

0 Downloads

Preview:

Click to see full reader

DESCRIPTION

Improvement Methodology: Introduction of ALERT Second Line Antibiotic Policy Steve McCormick Lead Antimicrobial Pharmacist NHS Lanarkshire. Restrictive Use Policy. Pilot across three acute sites in July 2009 Benchmark Practice => challenging areas first - PowerPoint PPT Presentation

TRANSCRIPT

Improvement Methodology: Introduction of ALERT Second Line Antibiotic Policy

Steve McCormickLead Antimicrobial Pharmacist

NHS Lanarkshire

Restrictive Use Policy

• Pilot across three acute sites in July 2009– Benchmark Practice => challenging areas

first

• Followed the Scottish Patient Safety Programme (SPSP) Test of Change approach – 1 => 3 => 5 spread

• Following analysis of pilot data, the policy was rolled out across all NHSL wards in January 2010

A PS D

Data A PS D

A PS D

“What does ALERT mean ?”

•Second•Line•Antibiotic •Policy

- Isobel Patterson C [Sister ICU MK]

Key Driver = Quality NOT Savings

Alert Antibiotic Issues Value Financial Years 2008/2009 and 2009/2010

£0.00

£10,000.00

£20,000.00

£30,000.00

£40,000.00

£50,000.00

£60,000.00

£70,000.00

Months

Iss

ue

s V

alu

e

FY 2008/2009

FY 2009/2010

SBAR REPORTDOTS

Appropriate PrescribingPiperacillin/Tazobactam Use

3026

30

86

1623

18

57

0

10

20

30

40

50

60

70

80

90

100

Monklands Hairmyres Wishaw Total

Hospital

No

of

form

s

No of patient episodes forPiperacillin/Tazobactom

No of patient episodes forpermitted indication (alsoexpressed as percentage)

88% 60%53%

66%

Non ALERT Use

Analysis of non-ALERT indication use of Piperacillin/Tazobactam

5 585

136

3

3

12

0

5

10

15

20

25

30

35

Monklands Hairmyres Wishaw Total

Hospital

No

of

form

s

d/w Micro - ALERT antibioticagreed

d/w Micro unknown outcome

Not d/w Micro

Site X

Total number of alert antibiotic forms completed = 81

Ward A Ward B Ward C Ward D Ward E Total

Tazocin 2 1 25 10 14 52Meropenem 1 1 3 2 6 13Ceftazidime - - - - - -IV

levofloxacin

- - 2 - 4 6

IV ciprofloxacin

- - - - 3 3

Usage Hotspots

• Monthly report will enable drill down to ward, consultant, patient – retrospective analysis of use

Role Models or Outliers

Pareto Chart Analysis

Piperacillin/Tazobactam use in Monklands (Feb 2010)

01

234

56

18 14 5 4 26 (ITU) 17 15 ERU 2 7

Ward

No

of

epis

od

es o

f u

se

0

20

40

60

80

100Cumulative percentage

No of episodes of use Cumulative percent

50%

“..but we use these all the time”

“Our area will be exempt”

“We are not joining the pilot”

“Ok FY’s will do it”

“Seems to be working”

“Non compliance – how can we minimise?”

top related